Similar articles

• Neuroprotection: a new strategy in the treatment of schizophrenia. Treatment of first-episode psychosis.

  Buckley PF. Buckley PF. CNS Spectr. 2007 Oct;12(10 Suppl 18):7-10. CNS Spectr. 2007. PMID: 19322958 Review. No abstract available.
• Neuroprotection: a new strategy in the treatment of schizophrenia. Early detection and intervention.

  Perkins DO. Perkins DO. CNS Spectr. 2007 Oct;12(10 Suppl 18):10-3. CNS Spectr. 2007. PMID: 19322959 Review. No abstract available.
• Pharmacology and mechanism of action of existing and new neuroleptics.

  Niemegeers CJ. Niemegeers CJ. Acta Psiquiatr Psicol Am Lat. 1990 Jan-Jun;36(1-2):26-36. Acta Psiquiatr Psicol Am Lat. 1990. PMID: 1981439 No abstract available.
• The CATIE study and its implications for antipsychotic drug use.

  Janicak PG. Janicak PG. Essent Psychopharmacol. 2006;7(1):53-63. Essent Psychopharmacol. 2006. PMID: 16989293 No abstract available.
• Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

  Stroup TS, Alves WM, Hamer RM, Lieberman JA. Stroup TS, et al. Nat Rev Drug Discov. 2006 Feb;5(2):133-46. doi: 10.1038/nrd1956. Nat Rev Drug Discov. 2006. PMID: 16518380 Review.